Enterprise Value
2.217M
Cash
146.3M
Avg Qtr Burn
-21.47M
Short % of Float
0.00%
Insider Ownership
5.40%
Institutional Own.
34.65%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Libmeldy / OTL-200 (ex vivo autologous gene therapy) Details Rare diseases, Central nervous system illness, Rare genetic disease | BLA Submission | |
OTL-203 (ex vivo autologous gene therapy) Details Metabolic disorder, Mucopolysaccharidosis Type 1 | Phase 2 Initiation | |
OTL-201 (ex vivo autologous gene therapy) Details Metabolic disorder, Eye disease , Sanfilippo Syndrome, Mucopolysaccharidosis type IIIA | Phase 1/2 Update | |
OTL-103 (ex vivo autologous gene therapy) Details WAS (Wiskott Aldrich syndrome) | Failed Discontinued |